Knowing When to Use Stereotactic Ablative Radiation Therapy in Oligometastatic Cancer

References

• HellmanS, WeichselbaumR. Oligometastases. J Clin Oncol. 1995;13(1):8–10. doi:10.1200/JCO.1995.13.1.87799047
   PubMed Web of Science ®Google Scholar
• BarneyJ, ChurchillE. Adenocarcinoma of the kidney with metastasis to the lung cured by nephrectomy and lobectomy. J Urol. 1939;42(3):269–276. doi:10.1016/S0022-5347(17)71516-9
   Google Scholar
• GuckenbergerM, LievensY, BoumaAB, et al. Characterisation and classification of oligometastatic disease: a European society for radiotherapy and oncology and European organisation for research and treatment of cancer consensus recommendation. Lancet Oncol. 2020;21(1):e18–e28. doi:10.1016/S1470-2045(19)30718-131908301
   PubMed Web of Science ®Google Scholar
• PalmaDA, OlsonR, HarrowS, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (sabr-comet): a randomised, phase 2, open-label trial. Lancet. 2019;393(10185):2051–2058. doi:10.1016/S0140-6736(18)32487-530982687
   PubMed Web of Science ®Google Scholar
• GomezDR, TangC, ZhangJ, et al. Local consolidative therapy vs maintenance therapy or observation for patients with oligometastatic non small-cell lung cancer: long-term results of a multi-institutional, Phase II, randomized study. J Clin Oncol. 2019;37(18):1558–1565. doi:10.1200/JCO.19.0020131067138
   PubMed Web of Science ®Google Scholar
• OstP, ReyndersD, DecaesteckerK, et al. Surveillance or metastasis directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol. 2018;36(5):446–453.29240541
   PubMed Web of Science ®Google Scholar
• IyengarP, WardakZ, GerberDE, et al. Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial. JAMA Oncol. 2018;4(1):e173501–e173501. doi:10.1001/jamaoncol.2017.350128973074
   PubMed Web of Science ®Google Scholar
• GalandiukS, WieandHS, MoertelCG, et al. Patterns of recurrence after curative resection of carcinoma of the colon and rectum. Surg Gynecol Obstet. 1992;174:27–32.1729745
   PubMedGoogle Scholar
• EliasD, BenizriE, VernereyD, et al. Preoperative criteria of incomplete resectability of peritoneal carcinomatosis from non-appendiceal colorectal carcinoma. Gastroenterol Clin Biol. 2005;29(10):1010–1013. doi:10.1016/S0399-8320(05)88175-816435508
   PubMedGoogle Scholar
• PfannschmidtJ, MuleyT, HoffmannH, et al. Prognostic factors and survival after complete resection of pulmonary metastases from colorectal carcinoma: experiences in 167 patients. J Thorac Cardiovasc Surg. 2003;126(3):732–739. doi:10.1016/S0022-5223(03)00587-714502146
   PubMed Web of Science ®Google Scholar
• YedibelaS, KleinP, FeuchterK, et al. Surgical management of pulmonary metastases from colorectal cancer in 153 patients. Ann Surg Oncol. 2006;13(11):1538–1544. doi:10.1245/s10434-006-9100-217009154
   PubMed Web of Science ®Google Scholar
• FernandezFG, DrebinJA, LinehanDC, et al. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg. 2004;240(3):438–447 discussion 447–50.
   Web of Science ®Google Scholar
• PawlikTM, ScogginsCR, ZorziD, et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg. 2005;241(5):715–722 discussion 722–4. doi:10.1097/01.sla.0000160703.75808.7d
   PubMed Web of Science ®Google Scholar
• KobielaJ, SpychalskiP, MarvasoG, et al. Ablative stereotactic radiotherapy for oligometastatic colorectal cancer: systematic review. Crit Rev Oncol Hematol. 2018;129:91–101. doi:10.1016/j.critrevonc.2018.06.005.30097241
   PubMed Web of Science ®Google Scholar
• ChoiHS, JeongBK, Mun KangK, et al. Tumor control and overall survival after stereotactic body radiotherapy for pulmonary oligometastases from colorectal cancer: a meta-analysis. Cancer Res Treat. 2020;52(4):1188–1198. doi:10.4143/crt.2020.402.32718145
   PubMed Web of Science ®Google Scholar
• LiS, DonD, GengJ, et al. Prognostic factors and optimal response interval for stereotactic body radiotherapy in patients with lung oligometastases or oligoprogression from colorectal cancer. Front Oncol. 2019;9:1080. doi:10.3389/fonc.2019.01080.;.31681609
   PubMed Web of Science ®Google Scholar
• JinguK, MatsuoY, OnishiH, et al. Dose escalation improves outcome in stereotactic body radiotherapy for pulmonary oligometastases from colorectal cancer. Anticancer Res. 2017;37(5):2709–2713. doi:10.21873/anticanres.11621.28476849
   PubMed Web of Science ®Google Scholar
• JooJH, ParkJ, KimJC, et al. Local control outcomes using stereotactic body radiation therapy for liver metastases from colorectal cancer. Int J Radiat Oncol Biol Phys. 2017;99(4):876–883. doi:10.1016/j.ijrobp.2017.07.030.29063852
   PubMed Web of Science ®Google Scholar
• ThompsonR, CheungP, ChuW, et al. Outcomes of extra-cranial stereotactic body radiotherapy for metastatic colorectal cancer: dose and site of metastases matter. Radiother Oncol. 2020;142:236–245. doi:10.1016/j.radonc.2019.08.018.31543287
   PubMed Web of Science ®Google Scholar
• YuJ, LiN, TangY, et al. Outcomes after hypofractionated stereotactic radiotherapy for colorectal cancer oligometastases. J Surg Oncol. 2019;119(4):532–538. doi:10.1002/jso.25361.30609038
   PubMed Web of Science ®Google Scholar
• Dell’AcquaV, SurgoA, KrajaF, et al. Stereotactic radiation therapy in oligometastatic colorectal cancer: outcome of 102 patients and 150 lesions. Clin Exp Metastasis. 2019;36(4):331–342. doi:10.1007/s10585-019-09976-z.31165360
   PubMed Web of Science ®Google Scholar
• SharmaA, BakerS, DuijmM, et al. Prognostic factors for local control and survival for inoperable pulmonary colorectal oligometastases treated with stereotactic body radiotherapy. Radiother Oncol. 2020;144:23–29. doi:10.1016/j.radonc.2019.10.004.31710940
   PubMed Web of Science ®Google Scholar
• ComitoT, CozziL, ClericiE, et al. Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach. BMC Cancer. 2014;14(1):619. doi:10.1186/1471-2407-14-619.25163798
   PubMed Web of Science ®Google Scholar
• BaeSH, KimMS, ChoCK, et al. High dose stereotactic body radiotherapy using three fractions for colorectal oligometastases. J Surg Oncol. 2012;106(2):138–143. doi:10.1002/jso.23058.22297789
   PubMed Web of Science ®Google Scholar
• KangJK, KimMS, KimJH, et al. Oligometastases confined one organ from colorectal cancer treated by SBRT. Clin Exp Metastasis. 2010;27(4):273–278. doi:10.1007/s10585-010-9325-0.20373133
   PubMed Web of Science ®Google Scholar
• JethwaKR, JangS, MullikinTC, et al. Association of tumor genomic factors and efficacy for metastasis-directed stereotactic body radiotherapy for oligometastatic colorectal cancer. Radiother Oncol. 2020;146:29–36. doi:10.1016/j.radonc.2020.02.008.32114263
   PubMed Web of Science ®Google Scholar
• FranzeseC, ComitoT, ToskaE, et al. Predictive factors for survival of oligometastatic colorectal cancer treated with Stereotactic body radiation therapy. Radiother Oncol. 2019;133:220–226. doi:10.1016/j.radonc.2018.10.024.30414754
   PubMed Web of Science ®Google Scholar
• JiX, ZhaoY, ZhuX, et al. Outcomes of stereotactic body radiotherapy for metastatic colorectal cancer with oligometastases, oligoprogression, or local control of dominant tumors. Front Oncol. 2021;10:595781. doi:10.3389/fonc.2020.595781.33585211
   PubMed Web of Science ®Google Scholar
• OttaianoA, ScottiV, De DivitiisC, et al. Integration of stereotactic radiotherapy in the treatment of metastatic colorectal cancer patients: a real practice study with long-term outcome and prognostic factors. Oncotarget. 2018;9(81):35251–35265. doi:10.18632/oncotarget.25834.30443292
   PubMedGoogle Scholar
• HoyerM, RoedH, Traberg HansenA, et al. Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol. 2006;45(7):823–830. doi:10.1080/02841860600904854.16982546
   PubMed Web of Science ®Google Scholar
• PitrodaSP, KhodarevNN, HuangL, et al. Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis. Nat Commun. 2018;9(1):20.29295995
   PubMed Web of Science ®Google Scholar
• NarayanRR, GoldmanDA, GonenM, et al. Peripheral circulating tumor DNA detection predicts poor outcomes after liver resection for metastatic colorectal cancer. Ann Surg Oncol. 2019;26:1824–1832.30706231
   PubMed Web of Science ®Google Scholar
• TsilimigrasDI, Ntanasis-StathopoulosI, BaganteF, et al. Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: a systematic review of the current evidence. Surg Oncol. 2018;27(2):280–288. doi:10.1016/j.suronc.2018.05.01229937183
   PubMed Web of Science ®Google Scholar
• NicosiaL, CucciaF, MazzolaR, et al. Disease course of lung oligometastatic colorectal cancer treated with stereotactic body radiotherapy. Strahlenther Onkol. 2020;196(9):813–820. doi:10.1007/s00066-020-01627-7.32399637
   PubMed Web of Science ®Google Scholar
• CornfordP, BellmuntJ, BollaM, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017;71(4):630–642. doi:10.1016/j.eururo.2016.08.00227591931
   PubMed Web of Science ®Google Scholar
• FakhrejahaniF, MadanRA, DahutWL. Management options for biochemically recurrent prostate cancer. Curr Treat Options Oncol. 2017;18(5):26. doi:10.1007/s11864-017-0462-428434181
   PubMed Web of Science ®Google Scholar
• KyriakopoulosCE, ChenYH, CarducciMA, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol. 2018;36(11):1080–1087. doi:10.1200/JCO.2017.75.3657.29384722
   PubMed Web of Science ®Google Scholar
• FizaziK, TranNP, FeinL, et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, Phase 3 trial. Lancet Oncol. 2019;20(5):686–700. doi:10.1016/S1470-2045(19)30082-8.30987939
   PubMed Web of Science ®Google Scholar
• OstP, BossiA, DecaesteckerK, et al. Metastasis- directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature. Eur Urol. 2015;67(5):852–863. doi:10.1016/j.eururo.2014.09.00425240974
   PubMed Web of Science ®Google Scholar
• KothariG, OstP, CheungP, et al. Trends in management of oligometastatic hormone-sensitive prostate cancer. Curr Oncol Rep. 2019;21(5):43. doi:10.1007/s11912-019-0791-5.30919165
   PubMed Web of Science ®Google Scholar
• NiaziT, ElaksharS, StroianG. Local ablative stereotactic body radiotherapy for oligometastatic prostate cancer. Curr Opin Support Palliat Care. 2018;12(3):351–358. doi:10.1097/SPC.0000000000000371.29979320
   PubMed Web of Science ®Google Scholar
• SchickU, JorcanoS, NouetP, et al. Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and/or distant metastases. Acta Oncol. 2013;52(8):1622–1628. doi:10.3109/0284186X.2013.764010.23544357
   PubMed Web of Science ®Google Scholar
• BowdenP, SeeAW, FrydenbergM, et al. Fractionated stereotactic body radiotherapy for up to five prostate cancer oligometastases: interim outcomes of a prospective clinical trial. Int J Cancer. 2020;146(1):161–168. doi:10.1002/ijc.32509.31199504
   PubMed Web of Science ®Google Scholar
• OstP, Jereczek-FossaBA, Van AsN, et al. Progression-free survival following stereotactic body radiotherapy for oligometastatic prostate cancer treatment-naive recurrence: a multi-institutional analysis. Eur Urol. 2016;69(1):9–12. doi:10.1016/j.eururo.2015.07.004.26189689
   PubMed Web of Science ®Google Scholar
• FranzeseC, ZucaliPA, Di BrinaL, et al. The efficacy of Stereotactic body radiation therapy and the impact of systemic treatments in oligometastatic patients from prostate cancer. CancerMed.2018;7(9):4379–4386. doi:10.1002/cam4.1707.
   Web of Science ®Google Scholar
• TriggianiL, MazzolaR, MagriniSM, et al. Metastasis‐directed stereotactic radiotherapy for oligoprogressive castration‐resistant prostate cancer: a multicenter study. World J Urol. 2019;37(12):2631–2637. doi:10.1007/s00345-019-02717-7.30859273
   PubMed Web of Science ®Google Scholar
• HurmuzP, OnalC, OzyigitG, et al. Treatment outcomes of metastasis-directed treatment using 68Ga-PSMA-PET/CT for oligometastatic or oligorecurrent prostate cancer: Turkish Society for Radiation Oncology group study (TROD 09-002). Strahlenther Onkol. 2020;196(11):1034–1043. doi:10.1007/s00066-020-01660-6.32617620
   PubMed Web of Science ®Google Scholar
• Jereczek-FossaBA, FanettiG, FodorC, et al. Salvage stereotactic body radiotherapy for isolated lymph node recurrent prostate cancer: single institution series of 94 consecutive patients and 124 lymph nodes. Clin Genitourin Cancer. 2017;15(4):e623–e632. doi:10.1016/j.clgc.2017.01.004.28185875
   PubMed Web of Science ®Google Scholar
• FranzeseC, Di BrinaL, D’AgostinoG, et al. Predictive factors for survival outcomes of oligometastatic prostate cancer patients treated with metastases‐directed therapy: a recursive partitioning‐based analysis. J Cancer Res Clin Oncol. 2019;145(10):2469–2479. doi:10.1007/s00432-019-03007-w.31444549
   PubMed Web of Science ®Google Scholar
• Lorenzo Livi. Phase II randomized trial of radiation therapy in oligometastatic mCRPC prostate cancer (ARTO).
   Google Scholar
• FrancoliniG, GarlattiP, LoiM, et al. ARTO trial (NCT03449719), a randomized phase II trial enrolling oligometastatic castration-resistant prostate cancer patients treated with first-line abiraterone acetate with or without stereotactic body radiation therapy: preliminary results comprehensive of biochemical outcomes and circulating tumor cells analysis. Journal of Clinical Oncology. 2021;39(6_suppl):118.
   Google Scholar
• van DesselLF, MartensJWM, LolkemaMP. Fundamentals of liquid biopsies in metastatic prostate cancer: from characterization to stratification. Curr Opin Oncol. 2020;32(5):527–534. doi:10.1097/CCO.0000000000000655.32675591
   PubMed Web of Science ®Google Scholar
• BjerreMT, NørgaardM, LarsenOH, et al. Epigenetic analysis of circulating tumor DNA in localized and metastatic prostate cancer: evaluation of clinical biomarker potential. Cells. 2020;9(6):1362. doi:10.3390/cells9061362.
   PubMed Web of Science ®Google Scholar
• PhillipsR, ShiWY, DeekM, et al. Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer. The ORIOLE phase 2 randomized clinical trial. JAMA Oncol. 2020;6(5):650–659. doi:10.1001/jamaoncol.2020.0147.32215577
   PubMed Web of Science ®Google Scholar
• CurranWJJr, PaulusR, LangerCJ, et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst. 2011;103(19):1452–1460. doi:10.1093/jnci/djr325.21903745
   PubMedGoogle Scholar
• AlbainKS, SwannRS, RuschVW, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet. 2009;374(9687):379–386. doi:10.1016/S0140-6736(09)60737-6.19632716
   PubMed Web of Science ®Google Scholar
• SalamaJK, HasselleMD, ChmuraSJ, et al. Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer. 2012;118(11):2962–2970. doi:10.1002/cncr.26611.22020702
   PubMed Web of Science ®Google Scholar
• AshworthA, RodriguesG, BoldtG, PalmaD. Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature. Lung Cancer. 2013;82(2):197–203. doi:10.1016/j.lungcan.2013.07.026.24051084
   PubMed Web of Science ®Google Scholar
• AshworthAB, SenanS, PalmaDA, et al. An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer. Clin Lung Cancer. 2014;15(5):346–355. doi:10.1016/j.cllc.2014.04.003.24894943
   PubMed Web of Science ®Google Scholar
• CollenC, ChristianN, SchallierD, et al. Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients. Ann Oncol. 2014;25(10):1954–1959. doi:10.1093/annonc/mdu370.25114022
   PubMed Web of Science ®Google Scholar
• ParikhRB, CroninAM, KozonoDE, et al. Definitive primary therapy in patients presenting with oligometastatic non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2014;89(4):880–887. doi:10.1016/j.ijrobp.2014.04.007.24867533
   PubMed Web of Science ®Google Scholar
• FranceschiniD, De RoseF, FranzeseC, et al. Predictive factors for response and survival in a cohort of oligometastatic patients treated with stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2019;104(1):111–121. doi:10.1016/j.ijrobp.2018.12.049.30630030
   PubMed Web of Science ®Google Scholar
• GriffioenGH, ToguriD, DaheleM, et al. Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): patient outcomes and prognostic factors. Lung Cancer. 2013;82(1):95–102. doi:10.1016/j.lungcan.2013.07.023.23973202
   PubMed Web of Science ®Google Scholar
• LiS, ZhuR, LiD, et al. Prognostic factors of oligometastatic non-small cell lung cancer: a meta-analysis. J Thorac Dis. 2018;10(6):3701–3713. doi:10.21037/jtd.2018.05.105.30069368
   PubMed Web of Science ®Google Scholar
• Hörner-RieberJ, BernhardtD, BlanckO, et al. Long-term follow-up and patterns of recurrence of patients with oligometastatic NSCLC treated with pulmonary SBRT. Clin Lung Cancer. 2019;20(6):e667–e677. doi:10.1016/j.cllc.2019.06.024.31327644
   PubMed Web of Science ®Google Scholar
• ChinAL, KumarKA, GuoHH, et al. Prognostic value of pretreatment FDG-PET parameters in high-dose image-guided radiotherapy for oligometastatic non-small-cell lung cancer. Clin Lung Cancer. 2018;19(5):e581–e588. doi:10.1016/j.cllc.2018.04.003.29759331
   PubMed Web of Science ®Google Scholar
• LussierYA, KhodarevNN, ReganK, et al. Oligo- and polymetastatic progression in lung metastasis(es) patients is associated with specific microRNAs. PLoS One. 2012;7(12):e50141. doi:10.1371/journal.pone.0050141.23251360
   PubMed Web of Science ®Google Scholar
• SenkusE, KyriakidesS, Penault-LlorcaF, et al.; ESMO Guidelines Working Group. Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi7–23. doi:10.1093/annonc/mdt284.23970019
   PubMed Web of Science ®Google Scholar
• ReyesDK, PientaKJ. The biology and treatment of oligometastatic cancer. Oncotarget. 2015;6(11):8491–8524. doi:10.18632/oncotarget.3455.25940699
   PubMedGoogle Scholar
• FisherB. Laboratory and clinical research in breast cancer–a personal adventure: the David A. Karnofsky Memorial Lecture Cancer Res. 1980;40(11):3863–3874.7008932
   PubMed Web of Science ®Google Scholar
• O’ShaughnessyJ. Extending survival with chemotherapy in metastatic breast cancer. Oncologist. 2005;10(Suppl 3):20–29. doi:10.1634/theoncologist.10-90003-20.16368868
   PubMed Web of Science ®Google Scholar
• LewisSL, PorcedduS, NakamuraN, et al. Definitive Stereotactic Body Radiotherapy (SBRT) for extracranial oligometastases: an international survey of >1000 radiation oncologists. Am J Clin Oncol. 2017;40(4):418–422. doi:10.1097/COC.0000000000000169.25647831
   PubMed Web of Science ®Google Scholar
• BartlettEK, SimmonsKD, WachtelH, et al. The rise in metastasectomy across cancer types over the past decade. Cancer. 2015;121(5):747–757. doi:10.1002/cncr.29134.25377689
   PubMed Web of Science ®Google Scholar
• KucharczykMJ, ParpiaS, Walker-DilksC, et al. Ablative therapies in metastatic breast cancer: a systematic review. Breast Cancer Res Treat. 2017;164(1):13–25. doi:10.1007/s10549-017-4228-2.28401364
   PubMed Web of Science ®Google Scholar
• MilanoMT, KatzAW, ZhangH, et al. Oligometastatic breast cancer treated with hypofractionated stereotactic radiotherapy: some patients survive longer than a decade. Radiother Oncol. 2019;131:45–51. doi:10.1016/j.radonc.2018.11.022.30773186
   PubMed Web of Science ®Google Scholar
• YooGS, YuJI, ParkW, et al. Prognostic factors in breast cancer with extracranial oligometastases and the appropriate role of radiation therapy. Radiat Oncol J. 2015;33(4):301–309. doi:10.3857/roj.2015.33.4.301.26756030
   PubMedGoogle Scholar
• FranzeseC, ComitoT, ViganòL, et al. Liver metastases-directed therapy in the management of oligometastatic breast cancer. Clin Breast Cancer. 2020;20(6):480–486. doi:10.1016/j.clbc.2020.05.006.32631769
   PubMed Web of Science ®Google Scholar
• WeykampF, KönigL, SeidensaalK, et al. Extracranial stereotactic body radiotherapy in oligometastatic or oligoprogressive breast cancer. Front Oncol. 2020;10:987. doi:10.3389/fonc.2020.00987.32676455
   PubMed Web of Science ®Google Scholar
• ScorsettiM, FranceschiniD, De RoseF, et al. Stereotactic body radiation therapy: a promising chance for oligometastatic breast cancer. Breast.2016;26:11–17. doi:10.1016/j.breast.2015.12.002.27017237
   PubMed Web of Science ®Google Scholar
• OnalC, GulerOC, YildirimBA. Treatment outcomes of breast cancer liver metastasis treated with stereotactic body radiotherapy. Breast.2018;42:150–156. doi:10.1016/j.breast.2018.09.006.30296648
   PubMed Web of Science ®Google Scholar
• KlementRJ, GuckenbergerM, AlheidH, et al. Stereotactic body radiotherapy for oligo-metastatic liver disease - Influence of pre-treatment chemotherapy and histology on local tumor control. Radiother Oncol. 2017;123(2):227–233. doi:10.1016/j.radonc.2017.01.013.28274491
   PubMed Web of Science ®Google Scholar
• HongJC, Ayala-PeacockDN, LeeJ, et al. Classification for long-term survival in oligometastatic patients treated with ablative radiotherapy: a multi-institutional pooled analysis. PLoS One. 2018;13(4):e0195149. doi:10.1371/journal.pone.0195149.29649281
   PubMed Web of Science ®Google Scholar
• DavidS, TanJ, SavasP, et al. Stereotactic ablative body radiotherapy (SABR) for bone only oligometastatic breast cancer: a prospective clinical trial. Breast.2020;49:55–62. doi:10.1016/j.breast.2019.10.016.31734589
   PubMed Web of Science ®Google Scholar
• TrovoM, FurlanC, PoleselJ, et al. Radical radiation therapy for oligometastatic breast cancer: results of a prospective phase II trial. Radiother Oncol. 2018;126(1):177–180. doi:10.1016/j.radonc.2017.08.032.28943046
   PubMed Web of Science ®Google Scholar